Selected research
Market Structure
Global Anti-Obesity Prescription Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Anti-Obesity Prescription Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Anti-Obesity Prescription Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Anti-Obesity Prescription Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Anti-Obesity Prescription Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Anti-Obesity Prescription Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Anti-Obesity Prescription Drugs include Novo Nordisk A/s, Glaxosmithkline, Vivus, Orexigen Therapeutics, F Hoffmann La Roche Ltd, Boehringer Ingelheim, Arena Pharmaceuticals and Alizyme, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Anti-Obesity Prescription Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Anti-Obesity Prescription Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Anti-Obesity Prescription Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Anti-Obesity Prescription Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Anti-Obesity Prescription Drugs Segment by Company
Novo Nordisk A/s
Glaxosmithkline
Vivus
Orexigen Therapeutics
F Hoffmann La Roche Ltd
Boehringer Ingelheim
Arena Pharmaceuticals
Alizyme
Anti-Obesity Prescription Drugs Segment by Type
Pediatric
Adult
Anti-Obesity Prescription Drugs Segment by Application
Hospitals Pharmacies
E-commerce
Retail Pharmacies
Anti-Obesity Prescription Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Obesity Prescription Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-Obesity Prescription Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Obesity Prescription Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Anti-Obesity Prescription Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Anti-Obesity Prescription Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Anti-Obesity Prescription Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Anti-Obesity Prescription Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Pediatric
- Adult
Applications
- Hospitals Pharmacies
- E-commerce
- Retail Pharmacies
Companies covered
- Novo Nordisk A/s
- Glaxosmithkline
- Vivus
- Orexigen Therapeutics
- F Hoffmann La Roche Ltd
- Boehringer Ingelheim
- Arena Pharmaceuticals
- Alizyme
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Anti-Obesity Prescription Drugs Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Anti-Obesity Prescription Drugs Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Anti-Obesity Prescription Drugs Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Anti-Obesity Prescription Drugs Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Anti-Obesity Prescription Drugs Market Dynamics
- 2.1 Anti-Obesity Prescription Drugs Industry Trends
- 2.2 Anti-Obesity Prescription Drugs Industry Drivers
- 2.3 Anti-Obesity Prescription Drugs Industry Opportunities and Challenges
- 2.4 Anti-Obesity Prescription Drugs Industry Restraints
3 Anti-Obesity Prescription Drugs Market by Manufacturers
- 3.1 Global Anti-Obesity Prescription Drugs Revenue by Manufacturers (2021-2026)
- 3.2 Global Anti-Obesity Prescription Drugs Sales by Manufacturers (2021-2026)
- 3.3 Global Anti-Obesity Prescription Drugs Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Anti-Obesity Prescription Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Anti-Obesity Prescription Drugs Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Anti-Obesity Prescription Drugs Manufacturers, Product Type & Application
- 3.7 Global Anti-Obesity Prescription Drugs Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Anti-Obesity Prescription Drugs Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Anti-Obesity Prescription Drugs Players Market Share by Revenue in 2025
- 3.8.3 2025 Anti-Obesity Prescription Drugs Tier 1, Tier 2, and Tier 3
4 Anti-Obesity Prescription Drugs Market by Type
- 4.1 Anti-Obesity Prescription Drugs Type Introduction
- 4.1.1 Pediatric
- 4.1.2 Adult
- 4.2 Global Anti-Obesity Prescription Drugs Sales by Type
- 4.2.1 Global Anti-Obesity Prescription Drugs Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Anti-Obesity Prescription Drugs Sales by Type (2021-2032)
- 4.2.3 Global Anti-Obesity Prescription Drugs Sales Market Share by Type (2021-2032)
- 4.3 Global Anti-Obesity Prescription Drugs Revenue by Type
- 4.3.1 Global Anti-Obesity Prescription Drugs Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Anti-Obesity Prescription Drugs Revenue by Type (2021-2032)
- 4.3.3 Global Anti-Obesity Prescription Drugs Revenue Market Share by Type (2021-2032)
5 Anti-Obesity Prescription Drugs Market by Application
- 5.1 Anti-Obesity Prescription Drugs Application Introduction
- 5.1.1 Hospitals Pharmacies
- 5.1.2 E-commerce
- 5.1.3 Retail Pharmacies
- 5.2 Global Anti-Obesity Prescription Drugs Sales by Application
- 5.2.1 Global Anti-Obesity Prescription Drugs Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Anti-Obesity Prescription Drugs Sales by Application (2021-2032)
- 5.2.3 Global Anti-Obesity Prescription Drugs Sales Market Share by Application (2021-2032)
- 5.3 Global Anti-Obesity Prescription Drugs Revenue by Application
- 5.3.1 Global Anti-Obesity Prescription Drugs Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Anti-Obesity Prescription Drugs Revenue by Application (2021-2032)
- 5.3.3 Global Anti-Obesity Prescription Drugs Revenue Market Share by Application (2021-2032)
6 Global Anti-Obesity Prescription Drugs Sales by Region
- 6.1 Global Anti-Obesity Prescription Drugs Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Anti-Obesity Prescription Drugs Sales by Region (2021-2032)
- 6.2.1 Global Anti-Obesity Prescription Drugs Sales by Region (2021-2026)
- 6.2.2 Global Anti-Obesity Prescription Drugs Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Anti-Obesity Prescription Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Anti-Obesity Prescription Drugs Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Anti-Obesity Prescription Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Anti-Obesity Prescription Drugs Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Anti-Obesity Prescription Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Anti-Obesity Prescription Drugs Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Anti-Obesity Prescription Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Anti-Obesity Prescription Drugs Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Anti-Obesity Prescription Drugs Revenue by Region
- 7.1 Global Anti-Obesity Prescription Drugs Revenue by Region
- 7.1.1 Global Anti-Obesity Prescription Drugs Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Anti-Obesity Prescription Drugs Revenue by Region (2021-2026)
- 7.1.3 Global Anti-Obesity Prescription Drugs Revenue by Region (2027-2032)
- 7.1.4 Global Anti-Obesity Prescription Drugs Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Anti-Obesity Prescription Drugs Revenue (2021-2032)
- 7.2.2 North America Anti-Obesity Prescription Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Anti-Obesity Prescription Drugs Revenue (2021-2032)
- 7.3.2 Europe Anti-Obesity Prescription Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Anti-Obesity Prescription Drugs Revenue (2021-2032)
- 7.4.2 Asia-Pacific Anti-Obesity Prescription Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Anti-Obesity Prescription Drugs Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Anti-Obesity Prescription Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Novo Nordisk A/s
- 8.1.1 Novo Nordisk A/s Company Information
- 8.1.2 Novo Nordisk A/s Business Overview
- 8.1.3 Novo Nordisk A/s Anti-Obesity Prescription Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Novo Nordisk A/s Anti-Obesity Prescription Drugs Product Portfolio
- 8.1.5 Novo Nordisk A/s Recent Developments
- 8.2 Glaxosmithkline
- 8.2.1 Glaxosmithkline Company Information
- 8.2.2 Glaxosmithkline Business Overview
- 8.2.3 Glaxosmithkline Anti-Obesity Prescription Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Glaxosmithkline Anti-Obesity Prescription Drugs Product Portfolio
- 8.2.5 Glaxosmithkline Recent Developments
- 8.3 Vivus
- 8.3.1 Vivus Company Information
- 8.3.2 Vivus Business Overview
- 8.3.3 Vivus Anti-Obesity Prescription Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Vivus Anti-Obesity Prescription Drugs Product Portfolio
- 8.3.5 Vivus Recent Developments
- 8.4 Orexigen Therapeutics
- 8.4.1 Orexigen Therapeutics Company Information
- 8.4.2 Orexigen Therapeutics Business Overview
- 8.4.3 Orexigen Therapeutics Anti-Obesity Prescription Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Orexigen Therapeutics Anti-Obesity Prescription Drugs Product Portfolio
- 8.4.5 Orexigen Therapeutics Recent Developments
- 8.5 F Hoffmann La Roche Ltd
- 8.5.1 F Hoffmann La Roche Ltd Company Information
- 8.5.2 F Hoffmann La Roche Ltd Business Overview
- 8.5.3 F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Product Portfolio
- 8.5.5 F Hoffmann La Roche Ltd Recent Developments
- 8.6 Boehringer Ingelheim
- 8.6.1 Boehringer Ingelheim Company Information
- 8.6.2 Boehringer Ingelheim Business Overview
- 8.6.3 Boehringer Ingelheim Anti-Obesity Prescription Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Boehringer Ingelheim Anti-Obesity Prescription Drugs Product Portfolio
- 8.6.5 Boehringer Ingelheim Recent Developments
- 8.7 Arena Pharmaceuticals
- 8.7.1 Arena Pharmaceuticals Company Information
- 8.7.2 Arena Pharmaceuticals Business Overview
- 8.7.3 Arena Pharmaceuticals Anti-Obesity Prescription Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Arena Pharmaceuticals Anti-Obesity Prescription Drugs Product Portfolio
- 8.7.5 Arena Pharmaceuticals Recent Developments
- 8.8 Alizyme
- 8.8.1 Alizyme Company Information
- 8.8.2 Alizyme Business Overview
- 8.8.3 Alizyme Anti-Obesity Prescription Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Alizyme Anti-Obesity Prescription Drugs Product Portfolio
- 8.8.5 Alizyme Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Anti-Obesity Prescription Drugs Value Chain Analysis
- 9.1.1 Anti-Obesity Prescription Drugs Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Anti-Obesity Prescription Drugs Production Mode & Process
- 9.2 Anti-Obesity Prescription Drugs Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Anti-Obesity Prescription Drugs Distributors
- 9.2.3 Anti-Obesity Prescription Drugs Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst